
Aditxt™: A biotech innovator enhancing life quality through nucleic acid-based immune health solutions.
Aditxt™ is a biotech innovation company founded with the mission to prolong life and enhance its quality by improving immune system health. The company focuses on nucleic acid-based technology to develop solutions that restore immune tolerance and provide long-lasting treatment for chronic diseases. Their flagship initiative, Adimune™, is in the pre-clinical stage and aims to address severe conditions by developing a robust pipeline of medications. Aditxt™ targets a global market, aiming to deliver significant advancements in immune health.
Notable affiliated individuals include Ruben Mislang, who plays a key role in the company's strategic direction. Aditxt™ has garnered attention from various investors interested in biotech innovations. Key achievements include the development of Adimune™, which holds promise for transforming the treatment landscape for chronic diseases. The overall impact of Aditxt™ lies in its potential to significantly improve the quality of life for individuals with severe immune-related conditions through pioneering nucleic acid-based therapies.

Inimmune
inimmune.com

Adimab
adimab.com

Adarx Pharmaceuticals
adarx.com

Adaptive Biotechnologies

ImmuneID

Aibios
aibios.com

Adcentrx Therapeutics
adcentrx.com

Nantkwest

Adtech Pharma
adtechpharma.com

AIM Immunotech
aimimmuno.com

Theradaptive
theradaptive.com

Imidomics
imidomics.com

Intellimedix

Aviceda Therapeutics
avicedarx.com

Adrx
adrxpharma.com
Companies similar to Aditxt include Inimmune, Adimab, Adarx Pharmaceuticals and Adaptive Biotechnologies.
Aditxt was founded in 2017.
Aditxt's headquarters is located in Richmond, VA, US.
Aditxt's most recent funding round was for $6M (USD) in December 2023.
As of Dec 29, 2023, Aditxt has raised a total of $60.3M (USD).
Aditxt has 175 employees as of Feb 6, 2024.